How should itraconazole be dosed and formulated for oropharyngeal, esophageal, systemic, and vulvovaginal candidiasis, and what are its contraindications and monitoring requirements?

Itraconazole for Candidiasis: Dosing, Formulations, and Clinical Use

Critical Formulation Distinction

Itraconazole oral solution must be used instead of capsules for candidiasis treatment due to 30% higher absorption and superior efficacy. 1 The capsule formulation has inadequate absorption and should be avoided for treating Candida infections. 2, 3

---

Oropharyngeal Candidiasis

Standard Dosing

• Itraconazole oral solution 200 mg once daily for 7-14 days is as effective as fluconazole 100 mg daily for 14 days, with a 97% clinical response rate. 4
• For HIV-infected children: 2.5-5 mg/kg/day has demonstrated efficacy. 1

Fluconazole-Resistant Disease

• First-line: Itraconazole oral solution ≥200 mg daily (up to 600 mg/day) provides 55-75% response rate in resistant disease. 2, 5
• Fluconazole-resistant isolates have 30% cross-resistance to itraconazole; susceptibility testing is recommended. 2
• Alternative: Posaconazole oral suspension 400 mg twice daily is preferred for resistant disease with 75% efficacy and better tolerability than itraconazole. 2

---

Esophageal Candidiasis

Standard Treatment

• Itraconazole oral solution 100-200 mg once daily for 3-8 weeks (continue for 2 weeks beyond symptom resolution) achieves 94% clinical response and 92% mycologic eradication. 6
• This regimen is clinically comparable to fluconazole for esophageal candidiasis in immunocompromised patients. 6

Fluconazole-Refractory Disease

• Itraconazole solution ≥200 mg daily for 14-21 days is the first-line alternative with 64-80% response rate. 7, 3
• Posaconazole suspension 400 mg twice daily for 28 days is recommended as first-line for resistant esophageal candidiasis. 2

Intravenous Formulation

• IV itraconazole: 200 mg every 12 hours for 4 doses (2 days), then 200 mg daily. 7, 1
• This formulation achieves adequate blood levels more rapidly with less variability than oral preparations. 7
• The IV formulation has not been studied in pediatric patients. 7

---

Vulvovaginal Candidiasis

Itraconazole 200 mg twice daily for one day achieves 70% cure rate with lower relapse rates (28.5%) compared to fluconazole single-dose therapy (53% relapse). 8 However, topical azoles or fluconazole remain standard first-line therapy per current guidelines.

---

Systemic/Invasive Candidiasis

Itraconazole is NOT recommended as first-line therapy for invasive candidiasis or candidemia. 1 Amphotericin B, fluconazole, or echinocandins are preferred agents. 7, 1

---

Contraindications and Drug Interactions

Major Contraindications

• Severe renal dysfunction for IV formulation due to cyclodextrin accumulation (though specific creatinine clearance cutoff not defined in candidiasis guidelines). 7
• Itraconazole inhibits cytochrome P450 enzymes; careful review of concomitant medications is mandatory. 7, 5

Monitoring Requirements

• Liver function tests should be monitored in patients receiving long-term azole therapy (>21 days). 2
• Monitor for drug-drug interactions, particularly with medications metabolized by CYP3A4. 5

---

Pediatric Considerations

• Itraconazole cyclodextrin oral solution 5 mg/kg/day provides potentially therapeutic concentrations, though levels are substantially lower than adults, particularly in children aged 6 months to 2 years. 7, 1
• For HIV-infected children with oropharyngeal candidiasis: 2.5-5 mg/kg/day is effective. 7, 1
• The IV formulation has not been studied in pediatric patients. 7

---

Common Pitfalls to Avoid

• Never use itraconazole capsules for candidiasis—only the oral solution or IV formulation should be used. 2, 3, 1
• Do not use itraconazole as first-line for invasive candidiasis—it is reserved for mucosal disease. 7, 1
• Absorption of oral solution is better on an empty stomach, unlike capsules which require food. 7
• Avoid topical agents in resistant disease due to low efficacy rates. 2
• Histamine receptor antagonists and proton pump inhibitors decrease capsule absorption (though solution formulation is preferred regardless). 7

---

Treatment Algorithm for Resistant Disease

1. Confirm resistant disease with species-level identification and susceptibility testing. 2
2. First-line: Posaconazole oral suspension 400 mg twice daily for 28 days. 2
3. Second-line: Itraconazole oral solution ≥200 mg daily (up to 600 mg/day). 2, 5
4. Reserve echinocandins as last resort due to parenteral administration and higher recurrence rates. 2